本试验旨在空腹吸入给药条件下，以药代动力学参数为终点指标，评估上海新黄河制药有限公司生产的CP006吸入粉雾剂（规格：195μg/5.5μg/27.5μg），本品一次两吸与对照制剂1（乌美溴铵吸入粉雾剂，规格：62.5μg，一次一吸），与对照制剂2信必可®都保®（布地奈德福莫特罗吸入粉雾剂（II），规格：160μg/4.5μg，一次四吸），与对照制剂1+对照制剂2，在单次给药相同剂量情况下，进行药代动力学特征比较。

[Translation]

This study aims to evaluate the pharmacokinetic parameters of CP006 inhalation powder (specification: 195μg/5.5μg/27.5μg) produced by Shanghai New Yellow River Pharmaceutical Co., Ltd. under the condition of fasting inhalation administration. The pharmacokinetic characteristics of this product (two inhalations at a time) are compared with control preparation 1 (umeclidinium inhalation powder, specification: 62.5μg, one inhalation at a time), control preparation 2 Symbicort® Turbuhaler® (budesonide and formoterol inhalation powder (II), specification: 160μg/4.5μg, four inhalations at a time), and control preparation 1 + control preparation 2 under the same dose of single administration.

Start Date-

Sponsor / Collaborator

Shanghai New Yellow River Pharmaceutical Co Ltd.

100 Clinical Results associated with CP006

100 Translational Medicine associated with CP006

100 Patents (Medical) associated with CP006

Literatures (Medical) associated with CP006

01 Aug 2011·Cancer Chemotherapy and PharmacologyQ4 · MEDICINE

Conjugation of chlorin p 6 to histamine enhances its cellular uptake and phototoxicity in oral cancer cells

Q4 · MEDICINE

Article

Author: Gupta, P. K. ; Parihar, Arpana ; Dube, Alok

PURPOSEOur previous studies in hamster cheek pouch model have shown that chlorin p (6) (Cp (6)), a chlorophyll derivative is a suitable photosensitizer for photodynamic treatment (PDT) of small tumors (<5 mm). However, for bigger tumors, the accumulation of Cp (6) was inadequate, which compromised the effectiveness of PDT. The purpose of present study was to investigate the possibility of improving the cellular uptake of Cp (6) by conjugating it to histamine, a biogenic amine that is known to modulate tumor growth and development via cell surface receptors.METHODSThe conjugate of Cp (6) and histamine (Cp (6)-his) was prepared by carbodiimide coupling reaction. Cellular uptake, intracellular localization and cytotoxicity of both Cp (6) and its conjugate were investigated in two human oral cancer cell lines (4451 and NT8e). The percentage of necrotic and apoptotic cells after PDT were also estimated using Hoechst 33342-propidium iodide staining.RESULTSIn both the cell line, the cellular uptake of Cp (6)-his was found to be ~10 times higher when compared to Cp (6). Histamine led to a slight increase in intracellular uptake of Cp (6)-his, whereas ranitidine, a histamine H2 receptor antagonist, and incubation at lower temperature (~15°C) led to its inhibition, suggesting that uptake of Cp (6)-his is receptor mediated. Results on western blot confirmed the presence of H2 receptor in both the cell line. Observations on intracellular localization revealed that unlike Cp (6), which localized on multiple sites, Cp (6)-his showed localization on the cell membrane and around the perinuclear region. Moreover, the phototoxicity induced by Cp (6)-his was ~4 times higher when compared to Cp (6) in both the cell lines. There was, however, no significant difference in the mode of cell death.CONCLUSIONResults suggest that conjugating Cp (6) with histamine can help improve the effectiveness of PDT in oral cancer cells by enhancing its intracellular delivery.

100 Deals associated with CP006

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Phase 1	CN	Shanghai New Yellow River Pharmaceutical Co Ltd.	07 Nov 2024
Pulmonary Disease, Chronic Obstructive	IND Approval	CN	Shanghai New Yellow River Pharmaceutical Co Ltd.	02 Feb 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

CP006

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation